Head to head
AstraZeneca vs Eli Lilly and Co
Side-by-side on the measures that matter, with a plain-English read. Full detail: AZN · LLY
AZN
AstraZeneca
159.20+0.26%
1-year price shape — -5% over the period
Quant Rating D · 33/100
vs
LLY
Eli Lilly and Co
1,179.27+0.83%
1-year price shape — +39% over the period
Quant Rating B · 77/100
1-year performance, rebased to 100
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co has the highest Quant Rating (77); Eli Lilly and Co has done best over the past year (+39%); Eli Lilly and Co earns the most per share.
| AZN | LLY | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - General | Drug Manufacturers - General |
| Last price | 159.20 | 1,179.27 |
| Change today | +0.26% | +0.83% |
| 1-year return | -4.8% | +38.7% |
| Market cap | $246.90B | $1.11T |
| 52-week range | 152.40 – 209.11 | 778.93 – 1,292.65 |
| Valuation | ||
| P/E (TTM) | 23.83 | 39.59 |
| P/E percentile, own 5-yr range | 11th | 6th |
| P/B | 4.91 | 32.77 |
| Dividend yield | 1.99% | 0.55% |
| Profitability & growth | ||
| EPS (TTM) | 6.54 | 22.95 |
| Net profit (TTM) | $10.14B | $21.60B |
| Revenue (TTM) | $61.37B | $79.67B |
| Revenue growth (YoY) | +6.4% | +47.7% |
| Gross margin | 81.9% | 83.4% |
| Operating margin | 22.1% | 49.7% |
| Net margin | 17.0% | 33.5% |
| Free cash flow (TTM) | $6.04B | $13.56B |
| Ownership & sentiment | ||
| Institutional ownership | 74.7% | 79.3% |
| Insider activity (12mo) | 6 buy / 2 sell | 37 buy / 13 sell |
| Short interest (% of float) | 0.2% | 0.7% |
| Analyst consensus | 87% buy / 7% hold / 7% sell (15) | 91% buy / 5% hold / 5% sell (22) |
| Analyst price target | $212 (+33%) | $1,383 (+17%) |
| StockVane view | ||
| StockVane Quant Rating | D (33) | B (77) |
| Company | ||
| Employees | 94,300 | 50,000 |
| Founded | 1913 | 1876 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.